Lowe Christopher P.'s Form 4 filing
Vincerx Pharma, Inc. (VINC) · filed Aug 26, 2022
- Accession no.
- 0000899243-22-029840
- Filed
- Aug 26, 2022
- Trade date
- Aug 24-25, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $49.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lowe Christopher P.CIK 0001376260 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents a weighted average purchase price. Actual purchase prices ranged from $1.638 to $1.649 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated.
Referenced by the price of 1 transaction in Table I.
- F2
Represents a weighted average purchase price. Actual purchase prices ranged from $1.6499 to $1.65 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated.
Referenced by the price of 1 transaction in Table I.